Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Cellectis S.A.NASDAQ: CLLS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $4.55M fell 7.7% year over year, behind the -2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.8% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.

Context

  • Depreciation & amortization amounted to 27.5% of revenue in FY2025, down 20.3 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -7.7% toward the trailing-twelve-month pace of -2.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.55M-10.8% QoQ
Last fiscal yearDec 2025
$20.06M+1.1% YoY
LTMMar 2026
$19.68M-2.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.7%——
1 year+1.1%——
3-year CAGR+2.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
20.06M USD
Year-over-year change
+1.1%
4-year CAGR
+9.1%

Depreciation & Amortization vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.6% is the 8th highest of 10, against a peer median of +3.1%.
  • Depreciation & amortization amounts to 28.9% of revenue for CLLS, versus a peer median of 62.7%.
CLLS Competitors
Depreciation & Amortization for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+2.9%28.9%
DBVTDBV Technologies S.A.LTM Mar 2026$12.36M USD+53.3%-27.5%—
KRROKorro Bio, Inc.LTM Mar 2026$3.44M USD-15.5%+19.5%89.4%
AMRNAmarin Corporation plcLTM Mar 2026$2.93M USD-1.6%-0.7%1.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$1.77M USD+61.3%+8.0%—
ACIUAC Immune S.A.LTM Mar 2026CHF 1.61M CHF-27.3%+2.0%43.6%
MREOMereo BioPharma Group plcLTM Mar 2026$1.25M USD+15.6%+8.7%249.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$605K USD+5.0%+24.6%—
SLNSilence Therapeutics plcLTM Mar 2026$577.79K USD—+4.5%62.7%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K USD+0.0%+3.2%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
Peer median (excluding CLLS) —+3.1%+3.9%62.7%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.